The University of Texas MD Anderson Cancer Center, Department of Lymphoma/Myeloma, is recruiting for a faculty member with active clinical research related to Myeloma. Physicians with clinical expertise in Lymphoma/Myeloma and strong clinical and/or translational research interests in Myeloma are strongly encouraged to apply. Faculty rank will be consistent with experience. The successful candidate will have the opportunity to participate in ongoing clinical and translational research with world-class physician scientists within The University of Texas MD Anderson Cancer Center. The program is composed of dynamic interdisciplinary leading clinicians and researchers dedicated to improving prevention, detection, diagnosis, prognosis and treatment of Myeloma. The selected candidate will assist with mentoring young faculty, fellows and other trainees, and contribute to the overall mission of the department.

The successful candidate will also have a background that demonstrates his/her ability to work synergistically with both laboratory-based and clinical faculty. Applicants should possess excellent writing and communication skills as evidenced by peer-reviewed publications, presentation skills for professional meetings, and the demonstrated ability to obtain extramural funding for clinical or translational research. MD Anderson Cancer Center offers many opportunities in a growing and vibrant research, clinical and training environment.

The salary range is competitive and is based on applicant's qualifications. Please send a letter of intent, curriculum vitae, names and addresses of three to five references, and a brief summary of past research accomplishments and future research plans to: jmrandall@mdanderson.org

The University of Texas MD Anderson Cancer Center is an equal opportunity employer and does not discriminate on the basis of race, color, national origin, gender, sexual orientation, age, religion, disability or veteran status except where distinction is required by law. All positions at MD Anderson Cancer Center are security sensitive and subject to examination of criminal history record information. Smoke-free and drug-free facility.

The division of hematology within the newly formed department of oncology at the CHUV is looking for:

**DEPUTY HEAD OF CLINIC WITH A FULL-TIME ACTIVITY**

The division of hematology offers an ideal medical environment with growing activities in all domains. In particular: i) we have observed a large increase in lymphoma/myeloma clinic, and ii) we are developing a departmental mission related to clinical expertise for such patients undergoing a newly developed immunotherapy program following specific translational departmental research developments.

Within this context the candidate should be a medical doctor with a specialty in hematology or oncology. She/he will supervise the clinic within the framework of the hematology specialty, with a high interest in lymphoma/myeloma patients and departmental developments as described above. She/he will also participate in the analyses and interpretation of the hematology laboratory tests (bone marrow smears, immunophenotypisation, and molecular biology).

Interested candidates should send a cover letter, a CV including publication list, and three recommendation letters to:

Professeur M.A. Duchosal
Service d’hématologie – CHUV
46, rue du Bugnon
1011 Lausanne
Switzerland

---

**Blood Classified Advertising**

*Blood* will accept advertisements for its Classified Advertising section only if they substantially relate to and further the American Society of Hematology’s tax-exempt purpose. ASH’s purpose is to engage exclusively in charitable, scientific, and educational activities and endeavors, including promoting and fostering, among the many scientific and clinical disciplines, the exchange and diffusion of information and ideas relating to blood and blood-forming tissues and encouraging investigations of hematologic matters.

Examples of advertisements that substantially relate to ASH’s purposes include advertisements for hematology-related employment at academic institutions that involve a research and/or an educational component, and advertisements for symposia and meetings that relate to furthering the exchange of hematology-related information and ideas.

To place an advertisement in *Blood’s* Classified Advertising section, please contact Valerie Marvin at the following address: Blood, 180 Old Tappan Road, Old Tappan, NJ 07675. Phone: 201-767-4170; fax: 201-767-8065; e-mail: vmarvin@cunnasso.com.

---

**Intermountain Healthcare**

Hem/One - Salt Lake City, Utah: The Intermountain Center for Hematological Malignancies seeks BC/BE attending physician candidates for our blood and marrow transplantation and acute leukemia therapy program. The candidate will join an experienced and dedicated multidisciplinary FACT accredited and FDA registered program, offering allogeneic (related and unrelated) and autologous SCT. Many patients are registered on institutional, SWOG and consortium investigational protocols. The Intermountain Blood and Marrow Transplant Program’s referral base consists of the Intermountain West area (Utah and surrounding states) and performs approximately 80 SCT’s yearly. The Acute Leukemia Program receives newly diagnosed acute leukemia patients who are candidates for intensive induction. The program currently employs 6 experienced transplant/leukemia Hem/One physicians and 10 midlevel providers as well as an extensive and excellent dedicated nursing and ancillary staff. Backup call will be shared equally between attendings.

Contact: Intermountain Healthcare, Physician Recruiting Attn: Wilf Rudert 800-888-3134 Fax: 801 442-3388. E-mail: PhysicianRecruit@imail.org. Web: http://physicianjobsintermountain.org
When a puzzle piece is missing …

Do you quit? Do you stop there?

Or do you do whatever it takes to complete the puzzle?

The ASH® Bridge Grant Program can help you find the missing piece you’re looking for.

Thousands of scientists may never complete their research puzzles if anticipated budget cuts prevent the NIH from funding approximately 2,300 research project grants in 2013. ASH is committed to ensuring that hematology research continues in hopes of discovering the next major medical breakthrough.

If you submitted a hematology-related NIH R01 grant in the past 18 months, but were denied funding due to budget cutbacks, ASH encourages you to apply for its new Bridge Grant Program.

To learn more and to apply, visit www.hematology.org/BridgeGrants.